ReviewThe Journal of experimental medicine2013
Neutralizing antibodies to HIV-1 induced by immunization.
Review in The Journal of experimental medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03980665 (The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART), which is not on this map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART
Who cites it
85 citing papers in PubMed, 135 citations in OpenAlex.
- HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.PloS one · 2016Trial
- Developing T Cell Epitope-Based Vaccines Against Infection: Challenging but Worthwhile.Vaccines · 2025Review
- Strategies for HIV-1 suppression through key genes and cell therapy.Frontiers in medicine · 2023Review
- Review
- Physicochemical characterization of the recombinant lectin scytovirin and microbicidal activity of the SD1 domain produced in rice against HIV-1.Plant cell reports · 2022Article
- Augmenting the Immune Response against a Stabilized HIV-1 Clade C Envelope Trimer by Silica Nanoparticle Delivery.Vaccines · 2021Article
- Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates.PLoS pathogens · 2021Article
- Polyfunctional Fc Dependent Activity of Antibodies to Native Trimeric Envelope in HIV Elite Controllers.Frontiers in immunology · 2020Article
- Characterization and Immunogenicity of HIV Envelope gp140 ZeraFrontiers in bioengineering and biotechnology · 2020Article
- Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses.The Journal of experimental medicine · 2019Article
- The potential of plant systems to break the HIV-TB link.Plant biotechnology journal · 2019Review
- Nucleic acid testing and molecular characterization of HIV infections.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Review
- Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques.Molecular therapy. Nucleic acids · 2019Article
- Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope.Journal of immunology research · 2019Article
- Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes.Scientific reports · 2018Article
- Unexpected synergistic HIV neutralization by a triple microbicide produced in rice endosperm.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Role of framework mutations and antibody flexibility in the evolution of broadly neutralizing antibodies.eLife · 2018Article
- Article
- Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies.Frontiers in immunology · 2018Review
- Systems serology: profiling vaccine induced humoral immunity against HIV.Retrovirology · 2017Review
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most neutralizing antibodies act at the earliest steps of viral infection and block interaction of the virus with cellular receptors to prevent entry into host cells. The inability to induce neutralizing antibodies to HIV has been a major obstacle to HIV vaccine research since the early days of the epidemic. However, in the past three years, the definition of a neutralizing antibody against HIV has been revolutionized by the isolation of extremely broad and potent neutralizing antibodies from HIV-infected individuals. Considerable hurdles remain for inducing neutralizing antibodies to a protective level after immunization. Meanwhile, novel technologies to bypass the induction of antibodies are being explored to provide prophylactic antibody-based interventions. This review addresses the challenge of inducing HIV neutralizing antibodies upon immunization and considers notable recent advances in the field. A greater understanding of the successes and failures for inducing a neutralizing response upon immunization is required to accelerate the development of an effective HIV vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.